Dicerna Pharmaceuticals (DRNA) Set to Announce Earnings on Thursday

Dicerna Pharmaceuticals (NASDAQ:DRNA) will release its earnings data after the market closes on Thursday, May 9th. Analysts expect Dicerna Pharmaceuticals to post earnings of ($0.22) per share for the quarter.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The firm had revenue of $1.54 million during the quarter, compared to analyst estimates of $8.38 million. Dicerna Pharmaceuticals had a negative net margin of 1,438.68% and a negative return on equity of 53.27%. On average, analysts expect Dicerna Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NASDAQ:DRNA opened at $13.32 on Tuesday. The stock has a market capitalization of $894.36 million, a price-to-earnings ratio of -11.10 and a beta of 2.30. Dicerna Pharmaceuticals has a 1-year low of $9.31 and a 1-year high of $17.98.

Several research firms have weighed in on DRNA. HC Wainwright reiterated a “buy” rating and issued a $22.00 target price on shares of Dicerna Pharmaceuticals in a report on Friday. ValuEngine lowered shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, April 26th. BidaskClub lowered shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. Zacks Investment Research lowered shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, March 14th. Finally, B. Riley boosted their target price on shares of Dicerna Pharmaceuticals from $21.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, March 13th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $22.13.

In other news, insider James B. Weissman sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $15.00, for a total value of $225,000.00. Following the sale, the insider now directly owns 39,480 shares of the company’s stock, valued at approximately $592,200. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 19.85% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2019/05/07/dicerna-pharmaceuticals-drna-set-to-announce-earnings-on-thursday.html.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Further Reading: How Important is Technical Analysis of Stocks

Earnings History for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.